News
Roche pauses Sarepta gene therapy shipments outside U.S.
Digest more
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months. Like ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Sarepta Therapeutics Inc. said Tuesday that its experimental muscular dystrophy drug eteplirsen met its goal in an extension study, and shares of the company more than doubled in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback